← Back to Clinical Trials
Recruiting NCT07081698

NCT07081698 Walnuts as an Infant Solid Food for Health

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07081698
Status Recruiting
Phase
Sponsor Colorado State University
Condition Gut -Microbiota
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-05-18
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 5 Months
Max Age 5 Months
Study Type INTERVENTIONAL
Interventions
Infant walnut intake

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-05-18 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective is to investigate the effect of walnuts on gut microbiota, inflammatory markers, atopic dermatitis status, and indices of allergy outcomes in breastfed infants during early complementary feeding. The three primary aims include: Aim 1: Evaluate the effect of walnut consumption on gut microbiota structure and function, inflammation, atopic dermatitis, and allergy outcomes. Aim 2: Evaluate the impact of walnut consumption on infant growth trajectories and risk of overweight. Aim 3 (exploratory): Identify walnut-specific food signatures that are associated with gut microbiota and immunity biomarkers using a novel nutri-metabolomics technique.

Eligibility Criteria

Inclusion Criteria: * Full term: gestational age ≥ 37 weeks * Generally healthy without conditions that would affect normal growth * No significant consumption of complementary food (e.g., no more than 1 oz of solid foods per week) * Exclusively breastfed (\< 2 weeks of cumulative formula exposure) Exclusion Criteria: * Adults unable to consent * Pregnant women * Prisoners

Contact & Investigator

Central Contact

Nathan Campbell, MS

✉ Nathan.Campbell@colostate.edu

📞 7655436716

Principal Investigator

Minghua Tang, Phd

PRINCIPAL INVESTIGATOR

Colorado State University

Frequently Asked Questions

Who can join the NCT07081698 clinical trial?

This trial is open to participants of all sexes, aged 5 Months or older, up to 5 Months, studying Gut -Microbiota. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07081698 currently recruiting?

Yes, NCT07081698 is actively recruiting participants. Contact the research team at Nathan.Campbell@colostate.edu for enrollment information.

Where is the NCT07081698 trial being conducted?

This trial is being conducted at Fort Collins, United States.

Who is sponsoring the NCT07081698 clinical trial?

NCT07081698 is sponsored by Colorado State University. The principal investigator is Minghua Tang, Phd at Colorado State University. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology